Olstein Capital Management L.P. Sells 11,877 Shares of Charles River Laboratories Intl. Inc (CRL)

Olstein Capital Management L.P. reduced its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 19.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,235 shares of the medical research company’s stock after selling 11,877 shares during the period. Olstein Capital Management L.P. owned approximately 0.10% of Charles River Laboratories Intl. worth $5,279,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of Charles River Laboratories Intl. by 2.3% during the second quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock valued at $128,288,000 after purchasing an additional 28,365 shares in the last quarter. Mackenzie Financial Corp increased its position in Charles River Laboratories Intl. by 81.7% in the third quarter. Mackenzie Financial Corp now owns 928,796 shares of the medical research company’s stock worth $100,329,000 after buying an additional 417,739 shares in the last quarter. Acadian Asset Management LLC increased its position in Charles River Laboratories Intl. by 27.4% in the fourth quarter. Acadian Asset Management LLC now owns 896,123 shares of the medical research company’s stock worth $98,081,000 after buying an additional 192,477 shares in the last quarter. Congress Asset Management Co. MA grew its position in shares of Charles River Laboratories Intl. by 2.0% during the fourth quarter. Congress Asset Management Co. MA now owns 771,279 shares of the medical research company’s stock worth $84,416,000 after purchasing an additional 15,201 shares in the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Charles River Laboratories Intl. during the second quarter worth about $65,915,000. 97.13% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Online Communications Bdirect sold 131,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $0.29, for a total value of $37,990.00. Also, Director C Richard Reese sold 10,227 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total value of $1,047,244.80. Following the completion of the sale, the director now directly owns 51,444 shares of the company’s stock, valued at $5,267,865.60. The disclosure for this sale can be found here. Insiders sold a total of 195,673 shares of company stock valued at $2,644,046 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Charles River Laboratories Intl. Inc (CRL) opened at $107.66 on Wednesday. The firm has a market capitalization of $4,830.40, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 1.50 and a beta of 0.74. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories Intl. Inc has a 1-year low of $85.00 and a 1-year high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.15. The business had revenue of $478.50 million during the quarter, compared to analyst estimates of $475.02 million. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the company earned $1.21 EPS. equities research analysts expect that Charles River Laboratories Intl. Inc will post 5.14 earnings per share for the current fiscal year.

Several research firms recently issued reports on CRL. Robert W. Baird set a $117.00 target price on Charles River Laboratories Intl. and gave the stock a “buy” rating in a research report on Monday, November 13th. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research report on Tuesday, October 24th. Evercore ISI started coverage on Charles River Laboratories Intl. in a report on Thursday, January 18th. They set an “in-line” rating and a $117.00 price target for the company. SunTrust Banks cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating and raised their price target for the company from $107.89 to $111.00 in a report on Monday, January 22nd. They noted that the move was a valuation call. Finally, Bank of America cut their price target on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $113.62.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/olstein-capital-management-l-p-sells-11877-shares-of-charles-river-laboratories-intl-inc-crl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply